Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q86U10

UPID:
LPP60_HUMAN

ALTERNATIVE NAMES:
Lysophospholipase-transacylase

ALTERNATIVE UPACC:
Q86U10; B9EGQ2; Q8IV80

BACKGROUND:
60 kDa lysophospholipase, known for its alternative name Lysophospholipase-transacylase, is integral to the body's lipid metabolism processes. It possesses multiple enzymatic functions, including the ability to catalyze transacylation reactions essential for phospholipid synthesis and remodeling. These activities are vital for the proper functioning of cellular membranes and the regulation of lipid signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of 60 kDa lysophospholipase unveils potential pathways for therapeutic intervention. Given its critical role in lipid metabolism and membrane physiology, targeting this protein could lead to novel treatments for conditions stemming from lipid imbalances and membrane dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.